Authors’ contributions
VVdE and LG contributed equally.
Disclosure statement
VVdE is an external research consultant for, and receives or has received consulting fees from: PsychoTropical Research, NeuraWell Therapeutics, Aristo Pharma GmbH; he has stock options in NeuraWell Therapeutics. LG has nothing to report. ST has received fees from NeuraWell Therapeutics for research unrelated to the present manuscript. PKG has equity interests in, and is on the advisory board of NeuraWell Therapeutics, the company that has the patent for a modified form of tranylcypromine.
Funding
The author(s) reported there is no funding associated with the work featured in this article.